NO923749L - Bcrf1-antagonister for behandling av epstein-barr-virusinfeksjoner - Google Patents

Bcrf1-antagonister for behandling av epstein-barr-virusinfeksjoner

Info

Publication number
NO923749L
NO923749L NO92923749A NO923749A NO923749L NO 923749 L NO923749 L NO 923749L NO 92923749 A NO92923749 A NO 92923749A NO 923749 A NO923749 A NO 923749A NO 923749 L NO923749 L NO 923749L
Authority
NO
Norway
Prior art keywords
bcrf1
epstein
antagonists
treatment
barr virus
Prior art date
Application number
NO92923749A
Other languages
English (en)
Other versions
NO923749D0 (no
Inventor
Kevin W Moore
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO923749L publication Critical patent/NO923749L/no
Publication of NO923749D0 publication Critical patent/NO923749D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Fremgangsmåte for behandling av EBV-infeksjoner. Fremgangsmåten omfat- ter tilførsel av en effektiv mengde av en antagonist til EBV-proteinet BCRF1. Antagonisten er fortrinnsvis et blok- kerende, monoklonalt antistoff spesi- fikt for BCRF1, eller et fragment eller et bindende preparat avledet fra dette. Oppfinnelsen omfatter bruk av en BCRF1- antagonist til f.eks. fremstilling av et medikament for behandling av Epstein-Barr-virussykdom.
NO923749A 1990-03-26 1992-09-25 Bcrf1-antagonister for behandling av epstein-barr-virusinfeksjoner NO923749D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49898590A 1990-03-26 1990-03-26
PCT/US1991/001812 WO1991014451A1 (en) 1990-03-26 1991-03-22 Bcrf1 antagonists for treating epstein-barr virus infections

Publications (2)

Publication Number Publication Date
NO923749L true NO923749L (no) 1992-09-25
NO923749D0 NO923749D0 (no) 1992-09-25

Family

ID=23983319

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923749A NO923749D0 (no) 1990-03-26 1992-09-25 Bcrf1-antagonister for behandling av epstein-barr-virusinfeksjoner

Country Status (23)

Country Link
US (1) US5756342A (no)
EP (1) EP0522010B1 (no)
JP (1) JP2509774B2 (no)
KR (1) KR960004856B1 (no)
CN (1) CN1056245A (no)
AT (1) ATE126704T1 (no)
AU (1) AU650013B2 (no)
CA (1) CA2079230C (no)
DE (1) DE69112392T2 (no)
DK (1) DK0522010T3 (no)
ES (1) ES2076526T3 (no)
FI (1) FI924278A0 (no)
GR (1) GR3017920T3 (no)
HU (1) HUT63339A (no)
IE (1) IE70910B1 (no)
IL (1) IL97629A0 (no)
MX (1) MX9203522A (no)
MY (1) MY106163A (no)
NO (1) NO923749D0 (no)
OA (1) OA09674A (no)
PT (1) PT97108B (no)
WO (1) WO1991014451A1 (no)
ZA (1) ZA912138B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010792A1 (en) * 1996-09-11 1998-03-19 Prendergast Patrick T Immune direction therapy
CN111574621B (zh) * 2020-04-30 2022-03-29 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种中和eb病毒的单克隆抗体及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4614810A (en) * 1984-09-24 1986-09-30 Pennwalt Corporation 4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof
US5231012A (en) * 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)

Also Published As

Publication number Publication date
ES2076526T3 (es) 1995-11-01
IL97629A0 (en) 1992-06-21
US5756342A (en) 1998-05-26
FI924278A (fi) 1992-09-24
DK0522010T3 (da) 1996-01-15
ATE126704T1 (de) 1995-09-15
CA2079230C (en) 2001-02-13
ZA912138B (en) 1991-12-24
KR960004856B1 (ko) 1996-04-16
GR3017920T3 (en) 1996-01-31
EP0522010A1 (en) 1993-01-13
EP0522010B1 (en) 1995-08-23
AU650013B2 (en) 1994-06-09
DE69112392D1 (de) 1995-09-28
PT97108B (pt) 1998-10-30
IE70910B1 (en) 1997-01-15
NO923749D0 (no) 1992-09-25
MX9203522A (es) 1992-07-01
FI924278A0 (fi) 1992-09-24
AU7588291A (en) 1991-10-21
JPH05501116A (ja) 1993-03-04
JP2509774B2 (ja) 1996-06-26
DE69112392T2 (de) 1996-02-01
OA09674A (en) 1993-05-15
IE910942A1 (en) 1991-10-09
MY106163A (en) 1995-03-31
CN1056245A (zh) 1991-11-20
WO1991014451A1 (en) 1991-10-03
PT97108A (pt) 1991-11-29
HUT63339A (en) 1993-08-30
CA2079230A1 (en) 1991-09-27

Similar Documents

Publication Publication Date Title
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
ES2058490T3 (es) Metodo de reducir respuestas de inmunoglobulina e.
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
PT1200126E (pt) Utilização de anticorpos monoclonais específicos de cd28 para a preparação de uma composição farmacêutica para o tratamento de infecções virais
DK0504307T3 (da) Fremgangsmåde til behandling af septisk shock
DK81691A (da) Fremgangsmaade til forhindring eller reduktion af eosinofili
FI944561A0 (fi) HIV:tä neutraloivia monoklonaalisia yhdistelmähumaanivasta-aineita HIV-infektion ehkäisemiseksi ja hoitamiseksi
NO923749D0 (no) Bcrf1-antagonister for behandling av epstein-barr-virusinfeksjoner
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
DK0470989T3 (da) Anvendelse af monoklonale anti-beta2 mikroglobulin antistoffer
DE68924963D1 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.